AGFAGDDAPR is a bioactive peptide that is a competitive and orally effective inhibitor of dipeptidyl peptidase-IV (DPP-IV). AGFAGDDAPR can enhance the level of GLP-1 in the body by inhibiting DPP-IV, thereby stimulating insulin secretion, improving beta-cell function, and inhibiting abnormal proliferation of alpha-cells, exerting anti-diabetic effects. AGFAGDDAPR can be used for research on type 2 diabetes[1].
Molecular Weight:
976.00
Purity:
98.01
CAS Number:
[330204-04-1]
Formula:
C41H61N13O15
Target:
Dipeptidyl Peptidase,GLP Receptor
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
